To summarize the last article: GLP-1 medications are reshaping modern medicine because they target the gut-brain-metabolic axis that drives most chronic disease - not just weight loss, but cardiovascular disease, heart failure, kidney disease, neurodegeneration, fatty liver, and systemic inflammation
Sometimes you need to start with a lower dose and titrate up in a way that fits the patient
Some manufacturers offer single-dose vials, and you draw the medication up yourself using the supplied needle and syringe
If successful, this could challenge existing oral GLP-1 offerings and expand patient choice by eliminating injections
Yes, injection site selection is important for GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)
Your provider determines medication type and dosing